​

Tandem Diabetes Care (TNDM) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

TNDM Stock Forecast

Tandem Diabetes Care (TNDM) stock forecast, based on 36 Wall Street analysts, predicts a 12-month average price target of $20.00, with a high of $24.00 and a low of $14.00. This represents a 61.68% increase from the last price of $12.37.

$10 $19 $28 $37 $46 $55 High: $24 Avg: $20 Low: $14 Last Closed Price: $12.37

TNDM Stock Rating

Tandem Diabetes Care stock's rating consensus is Buy, based on 36 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 22 Buy (61.11%), 13 Hold (36.11%), 1 Sell (2.78%), and 0 Strong Sell (0.00%).

Buy
Total 36 1 13 22 Strong Sell Sell Hold Buy Strong Buy

TNDM Price Target Upside V Benchmarks

TypeNameUpside
StockTandem Diabetes Care61.68%
SectorHealthcare Stocks 13.55%
IndustryMedical Device Stocks16.49%

Price Target Trends

1M3M12M
# Anlaysts1311
Avg Price Target$22.00$20.00$35.82
Last Closing Price$12.37$12.37$12.37
Upside/Downside77.85%61.68%189.57%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 253613-123
Aug, 2546101122
Jul, 254611-122
Jun, 254710-122
May, 254810-123
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Sep 08, 2025Suraj KaliaOppenheimer$22.00$12.5076.00%77.85%
Aug 07, 2025William PlovanicCanaccord Genuity$24.00$11.20114.29%94.02%
Aug 07, 2025Matt O'BrienPiper Sandler$14.00$14.39-2.71%13.18%
Mar 05, 2025Morgan Stanley$22.00$19.1115.12%77.85%
Feb 28, 2025Bernstein$25.00$22.1412.92%102.10%
Jan 08, 2025Lee HambrightBernstein$44.00$37.4917.36%255.70%
Nov 07, 2024Jeff JohnsonRobert W. Baird$37.00$32.8712.56%199.11%
Nov 05, 2024Lee HambrightBernstein$42.00$33.1126.85%239.53%
Oct 04, 2024David RomanGoldman Sachs$46.00$39.9915.03%271.87%
Oct 02, 2024Shagun SinghRBC Capital$65.00$41.0758.27%425.46%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 12, 2025CitigroupNeutralNeutralupgrade
Aug 11, 2025Lake StreetBuyHolddowngrade
Aug 07, 2025Piper SandlerOverweightNeutraldowngrade
May 22, 2025CitigroupNeutralNeutralhold
Jan 08, 2025BernsteinOutperformOutperformhold
Nov 05, 2024BernsteinOutperforminitialise
Oct 04, 2024Goldman SachsNeutralinitialise
Oct 02, 2024RBC CapitalOutperforminitialise
Oct 01, 2024CitigroupBuyBuyhold
Sep 23, 2024Wells FargoBuyBuyhold

Financial Forecast

EPS Forecast

$-4 $-3 $-2 $-1 $0 $1 Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-0.56$0.25$-1.47$-3.43$-1.47----
Avg Forecast$-0.72$0.30$-1.09$-3.21$-1.69$-1.22$-0.76$-0.27$-0.07
High Forecast$-0.70$0.32$-1.07$-2.99$-1.35$-0.78$-0.19$0.34$-0.06
Low Forecast$-0.76$0.30$-1.13$-3.39$-1.77$-1.43$-1.08$-0.66$-0.07
Surprise %-22.22%-16.67%34.86%6.85%-13.02%----

Revenue Forecast

$450M $640M $830M $1B $1B $1B Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$498.83M$702.80M$801.22M$747.72M$940.20M----
Avg Forecast$472.10M$691.83M$802.00M$764.45M$909.25M$1.01B$1.13B$1.25B$1.37B
High Forecast$495.47M$726.08M$823.70M$768.90M$935.20M$1.03B$1.13B$1.27B$1.40B
Low Forecast$463.07M$678.59M$790.66M$755.55M$902.72M$999.97M$1.12B$1.23B$1.34B
Surprise %5.66%1.59%-0.10%-2.19%3.40%----

Net Income Forecast

$-350M $-270M $-190M $-110M $-30M $50M Dec 20 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 20Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-34.38M$15.57M$-94.59M$-222.61M$-96.03M----
Avg Forecast$-13.42M$20.84M$21.80M$-222.61M$-101.26M$-78.17M$-44.51M$-14.71M$-4.22M
High Forecast$-4.46M$27.73M$29.60M$-135.07M$-87.83M$-50.98M$-12.35M$22.31M$-4.13M
Low Forecast$-22.38M$13.95M$13.99M$-310.15M$-114.70M$-92.69M$-70.45M$-43.04M$-4.35M
Surprise %156.18%-25.30%-533.97%--5.17%----

TNDM Forecast FAQ

Is Tandem Diabetes Care stock a buy?

Tandem Diabetes Care stock has a consensus rating of Buy, based on 36 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 22 Buy, 13 Hold, 1 Sell, and 0 Strong Sell, reflecting a consensus that Tandem Diabetes Care is a favorable investment for most analysts.

What is Tandem Diabetes Care's price target?

Tandem Diabetes Care's price target, set by 36 Wall Street analysts, averages $20 over the next 12 months. The price target range spans from $14 at the low end to $24 at the high end, suggesting a potential 61.68% change from the previous closing price of $12.37.

How does Tandem Diabetes Care stock forecast compare to its benchmarks?

Tandem Diabetes Care's stock forecast shows a 61.68% upside, outperforming the average forecast for the healthcare stocks sector (13.55%) and outperforming the medical device stocks industry (16.49%).

What is the breakdown of analyst ratings for Tandem Diabetes Care over the past three months?

  • September 2025: 13.04% Strong Buy, 26.09% Buy, 56.52% Hold, 0% Sell, 4.35% Strong Sell.
  • August 2025: 18.18% Strong Buy, 27.27% Buy, 45.45% Hold, 4.55% Sell, 4.55% Strong Sell.
  • July 2025: 18.18% Strong Buy, 27.27% Buy, 50.00% Hold, 0% Sell, 4.55% Strong Sell.

What is Tandem Diabetes Care’s EPS forecast?

Tandem Diabetes Care's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.22, marking a -17.01% decrease from the reported $-1.47 in 2024. Estimates for the following years are $-0.76 in 2026, $-0.27 in 2027, and $-0.07 in 2028.

What is Tandem Diabetes Care’s revenue forecast?

Tandem Diabetes Care's average annual revenue forecast for its fiscal year ending in December 2025 is $1.01B, reflecting a 7.58% increase from the reported $940.2M in 2024. The forecast for 2026 is $1.13B, followed by $1.25B for 2027, and $1.37B for 2028.

What is Tandem Diabetes Care’s net income forecast?

Tandem Diabetes Care's net income forecast for the fiscal year ending in December 2025 stands at $-78.171M, representing a -18.59% decrease from the reported $-96.025M in 2024. Projections indicate $-44.508M in 2026, $-14.707M in 2027, and $-4.223M in 2028.